Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
about
Carbapenems: past, present, and futureGenetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibioticsTranscriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in IndiaMolecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms.Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcomeCellular impermeability and uptake of biocides and antibiotics in Gram-negative bacteria.Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolatesDifferential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosaAntibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Pseudomonas aeruginosa: resistance to the maxEmergence of carbapenem resistance due to the novel insertion sequence ISPa8 in Pseudomonas aeruginosaThe role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists.Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosaPolyamine effects on antibiotic susceptibility in bacteria.Presence of Pseudomonas putida strains harboring plasmids bearing the metallo-beta-lactamase gene bla(IMP) in a hospital in Japan.The resistance mechanisms of b-lactam antimicrobials in clinical isolates of Acinetobacter baumanniiDevelopment of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.Efflux-mediated antimicrobial resistance.High-throughput automated microfluidic sample preparation for accurate microbial genomics.Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutationOXA-type carbapenemases.Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.AmpC beta-lactamases.Outcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.The emergence of carbapenem resistant Klebsiella pneumoniae in Malaysia: correlation between microbiological trends with host characteristics and clinical factors.Molecular Dynamics Computer Simulations of Multidrug RND Efflux PumpsMultidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Transporter and its engineering for secondary metabolites.Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone.Evaluation of the Osiris expert system for identification of beta-lactam phenotypes in isolates of Pseudomonas aeruginosa.Metallo-β-lactamase-producing clinical isolates from patients of a tertiary care hospital.Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
P2860
Q24634999-6EA518C2-5DA7-46AA-A9ED-756B74DF5A51Q28493162-3ABABC85-8FB9-4569-BCB4-5E5FF2678A9EQ28546847-82A26419-D35B-4300-96CF-D109FFD8CC6AQ33648133-67CFF170-9C47-46E0-862C-2CECA2561E9DQ34106854-9BF0C848-0ACF-4052-B6A9-721CABDFCDECQ34631433-436A4418-5FC3-4822-ADAC-7204E72DC5D7Q34648729-27435D23-EFE0-498F-A8B4-31AF5A98308CQ34680681-87E8E2B8-5290-4A03-BFB6-DEC44C0A15D6Q35007624-FF34E76D-C634-46A0-972D-E7C48B4BC9D5Q35084559-76B21F2E-71AE-4269-9758-E3F8F71A6917Q35116174-192256BC-E325-4E98-BE30-0C8036BBF0EFQ35186545-C3136EF1-B1DB-49DF-ABA8-907EBD672B68Q35830489-3D1853E0-B5D3-4D64-A8CE-CD11BA033B31Q35840831-5A76AC29-0ABF-48F4-B011-4E5F410A7CA3Q35922362-5577B628-1F62-4DDA-B537-0EACF88A1542Q35937324-BD51CFBD-7708-4109-B1EA-A42F00FB8510Q36095041-53BD80DC-BE32-4180-A878-13D741848DFCQ36138147-901548AC-B5CF-408E-9B29-751394C62B21Q36262179-46CEC8F7-C9B2-40B8-9407-3E9696882795Q36295397-665D5A90-2A93-4A47-9AE2-3431A897324CQ36381840-AD341DAD-38ED-406D-AD5D-9340AC95258BQ36804049-77CC625D-1A19-4142-A314-879564AEE0F2Q37302114-2D053AD2-E63E-4E54-964F-4C340F062CCAQ37366249-F64B8340-4ECF-4A14-B951-2D9CD578D477Q37518263-FC4218EA-7120-436E-8765-33EEB3FD7083Q37569441-A723FAD9-9D07-4988-AA7D-37A15CF556D1Q37655085-70D3E3D9-7AA7-4EB0-B087-1BB5F39C7768Q37656243-7BA8C84A-028A-42D8-AC63-F0947F642AD8Q37993716-4E64F287-1712-423C-8BDA-C037367F4110Q38751264-10C96622-CFC1-4A66-ACAC-F55E3B722F87Q38840814-3B5A5609-04AB-4973-A403-65F3FB25DE18Q39071995-BE898591-696F-4318-972F-E070B00378F3Q39097378-097FB8B3-990B-4745-B310-3C33BF7E3047Q39120027-78E3A4C4-9FC1-4E5F-813A-5FBEA7731BC7Q39755440-44605333-F025-417E-83FA-4DD53EE2A6A0Q39848627-9922C89E-02CC-4112-91D4-7C5B8DCB27FFQ40105032-3F5AC2DE-2B0A-49C8-BA44-66800FB66DC7Q40282230-6077B64A-5B14-4C5D-B084-6C88F3CC3776Q40306198-796EA818-9867-4489-9105-DAD6E2884648Q40334912-0D830D23-E62D-4132-89B5-1805D9E633F3
P2860
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@ast
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@en
type
label
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@ast
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@en
prefLabel
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@ast
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@en
P2093
P2860
P1476
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates
@en
P2093
P2860
P304
P356
10.1128/AAC.45.2.480-484.2001
P407
P577
2001-02-01T00:00:00Z